Close Menu

NEW YORK (GenomeWeb) – Vela Diagnostics has submitted a next-generation sequencing assay that detects HIV-1 drug resistance mutations (DRMs) to the US Food and Drug Administration, the company announced today.  

The Sentosa SQ HIV Genotyping Assay can be used on plasma samples from patients with HIV-1 infection to detect HIV-1 Group M genomic DRMs in the protease, reverse transcriptase, and integrase regions of the pol gene. Resistance to antiretroviral drugs as a result of DRMs is the most common cause of therapeutic failure in HIV treatment.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.